Biodegradable nanoparticles for the treatment of epilepsy: from current advances to future challenges

dc.commentsCEB55037por
dc.contributor.authorBonilla, Lorenapor
dc.contributor.authorEsteruelas, Gerardpor
dc.contributor.authorEttcheto, Mirenpor
dc.contributor.authorEspina, Martapor
dc.contributor.authorGarcía, María Luisapor
dc.contributor.authorCamins, Antonipor
dc.contributor.authorSouto, Eliana B.por
dc.contributor.authorCano, Amandapor
dc.contributor.authorSánchez-López, Elenapor
dc.date.accessioned2022-08-07T20:48:10Z
dc.date.available2022-08-07T20:48:10Z
dc.date.issued2022
dc.date.updated2022-08-06T10:12:52Z
dc.description.abstractEpilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized by an electrical abnormal activity in different brain regions. The massive entrance of Ca2+ into neurons is the main neurotoxic process that lead to cell death and finally to neurodegeneration. Although there are a huge number of antiseizure medications, there are many patients who do not respond to the treatments and present refractory epilepsy. In this context, nanomedicine constitutes a promising alternative to enhance the central nervous system bioavailability of antiseizure medications. The encapsulation of different chemical compounds at once in a variety of controlled drug delivery systems gives rise to an enhanced drug effectiveness mainly due to their targeting and penetration into the deepest brain region and the protection of the drug chemical structure. Thus, in this review we will explore the recent advances in the development of drugs associated with polymeric and lipid based nanocarriers as novel tools for the management of epilepsy disorders.por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion
dc.description.sponsorshipAmanda Cano acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I). Authors acknowledge the support of the Spanish Ministry of Economy and Ccompetitiveness under project SAF2017-84283-R; Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED, CB06/05/0024) and Portuguese Science and Technology Foundation (FCT) for the strategic fund (UIDB/04469/2020).por
dc.distributioninternationalpor
dc.identifier.citationBonilla, Lorena; Esteruelas, Gerard; Ettcheto, Miren; Espina, Marta; García, María Luisa; Camins, Antoni; Souto, Eliana B.; Cano, Amanda; Sánchez-López, Elena, Biodegradable nanoparticles for the treatment of epilepsy: from current advances to future challenges. Epilepsia Open, 76(S1), S121-S132, 2022por
dc.identifier.doi10.1002/epi4.12567por
dc.identifier.issn2470-9239por
dc.identifier.pmid34862851por
dc.identifier.urihttps://hdl.handle.net/1822/79263
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherWileypor
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04469%2F2020/PTpor
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/journal/24709239por
dc.rightsopenAccesspor
dc.subjectEpilepsypor
dc.subjectLipid nanoparticlespor
dc.subjectNanomedicinepor
dc.subjectNanotechnologypor
dc.subjectNeurodegenerative diseasespor
dc.subjectPolymeric nanoparticlespor
dc.subject.wosScience & Technologypor
dc.titleBiodegradable nanoparticles for the treatment of epilepsy: from current advances to future challengespor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationEndPageS132por
oaire.citationIssueS1por
oaire.citationStartPageS121por
oaire.citationVolume7por
sdum.journalEpilepsiapor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_55037_1.pdf
Tamanho:
14.48 MB
Formato:
Adobe Portable Document Format